By uncovering the biological mechanisms behind repair and regeneration, ARMI is helping lay the foundations for new therapies for injury, disease and age-related decline. Delivering these therapies to the people who need them is a strategic priority. Our spinout companies mark that translation in progress, carrying preclinical research toward first-in-human trials. 

ARMI’s spinout companies are: 

Orio Therapeutics

Orio Therapeutics has developed technology modifying the therapeutic proteins that control localisation after injection, improving tissue repair at lower doses while reducing costs and side effects. In doing so, they allow the injected molecule to stay at the injection site, improving tissue regeneration and repair at lower doses while reducing costs and side effects.

Orio has prioritised their new technology for patients with myocardial infarction, assisting in the preservation of cardiac function and reducing fibrosis and cellular death following a heart attack. With this emergent technology capable of modifying any protein-based therapeutic, Orio has the potential to transform the field of regenerative medicine, drastically improving therapies that could change the lives of sufferers of fibrosis.

Year established: 2023
Lead researcher and co-founder: Professor Mikaël Martino
Website: oriotx.com

Myostellar Pty Ltd 

Myostellar is developing novel therapies for the treatment of muscular dystrophies which can stimulate skeletal muscle regeneration with minimal fibrosis. There are currently no therapeutics that do so, and Myostellar’s research is showing great promise for sufferers of muscular dystrophy and acute muscle injury which could lead to life-changing improvements in the lives of countless patients. 

Year established: 2022
Lead researchers: Professor Peter Currie and Professor Mikaël Martino
Website: myostellar.com

Mogrify

Mogrify has developed proprietary technologies that can direct cellular reprogramming and the maintenance of cell identity, affecting a direct transdifferentiation from one mature cell type to another. This provides researchers with the template for turning human cells into any desired cell, even vital organs, potentially revolutionising treatments for degenerative diseases and transforming the lives of patients, with a current focus on ophthalmology, otology and metabolic disease.

Year established: 2016
Researchers: Professor Jose Polo, Professor Owen Rackham (University of Bristol), Professor Julian Gough (University of Bristol)
Website: mogrify.co.uk